For a long time, the fight against Parkinson’s disease has been about managing the fallout—finding better ways to live with the symptoms rather than stopping the disease itself. But that might all be changing. In a breakthrough that sounds almost too good to be true, researchers realized that a drug we already use to treat cancer shows a remarkable ability to stop the progression of Parkinson’s in the lab.

Think about that for a second. An FDA-approved cancer drug.

The discovery is a story of elegant detective work, revealing how Parkinson’s actually spreads from one cell to another. It shows how this unexpected tool from oncology could be used to block the disease’s path, and it points to something profound—not just about medicine, but about the deeper wisdom built right into our own biology.

A New Understanding of Parkinson’s

The familiar signs of Parkinson’s—a tremor in a hand, a growing stiffness in the body—are the final expressions of a quiet war taking place deep inside the brain. For decades, the focus has been on the loss of dopamine, a critical chemical messenger for movement and mood. As the brain cells that produce it die off, the disease’s symptoms emerge. Most treatments work to replenish this lost dopamine, which is a vital way to manage the condition. But a deeper question has always loomed: What is actually causing these cells to die, and how does the destruction spread?

At the heart of the mystery is a protein called alpha-synuclein. In its healthy state, it’s a helpful part of our neural architecture, allowing nerve cells to communicate effectively. The problem begins when this protein misfolds, twisting into a destructive shape.

This single event triggers a chain reaction. Like a bad influence, one misfolded protein encourages its healthy neighbors to adopt the same damaged form. They start clumping together into toxic aggregates known as Lewy bodies, which choke the neuron from the inside and ultimately kill it.

This insight has completely changed how we see Parkinson’s. It isn’t just a passive decay of brain tissue; it’s an active disease that spreads itself. Researchers now know this happens through a “prion-like” process. When a neuron dies, it releases these toxic alpha-synuclein “seeds” into the brain. Healthy neurons nearby can then absorb these seeds, which in turn corrupt the healthy proteins within them. The disease hijacks the cell’s own machinery to fuel its spread. To truly alter the course of Parkinson’s, managing the damage isn’t enough. We have to find a way to sever this chain of transmission and contain the fire.

How a Toxic Protein Invades Healthy Cells

If Parkinson’s pathology spreads by infecting healthy brain cells, it raises a critical question: How does the toxic alpha-synuclein get inside? A protein can’t just wander into a cell. It needs a specific point of entry, a kind of molecular doorway that recognizes it and grants it access. For years, finding this doorway has been a primary focus for a team of researchers at the Johns Hopkins University School of Medicine.

Their investigation unfolded like a great detective story. An early breakthrough came when the team identified a suspect: a protein on the surface of neurons called Lag3. They discovered that Lag3 could bind to the toxic alpha-synuclein, helping it get inside the cell. It was a huge step forward, but it wasn’t the whole story. Blocking Lag3 slowed the invasion, but didn’t stop it completely, a clear sign that it had an accomplice. As neuroscientist Valina Dawson explains, “Our work previously demonstrated that Lag3 wasn’t the only cell surface protein that helped neurons absorb alpha-synuclein, so we turned to Aplp1 in our most recent experiments.”

With that, they found the second piece of the puzzle: another protein called Aplp1. The truly profound discovery, however, was that these two proteins work together. They form a physical partnership on the cell’s surface, creating a unique docking station perfectly shaped to grab onto the toxic alpha-synuclein. The researchers described them as acting like “twin door handles” that must be engaged at the same time to open the door and let the toxic cargo in.

To prove this, the team conducted a beautifully clear experiment using genetically engineered mice. Mice that were missing just one of the proteins—either Aplp1 or Lag3—showed some protection from the disease. But the smoking gun came from the mice that were missing both. In these “double knockout” mice, the uptake of toxic alpha-synuclein into brain cells dropped by an astonishing 90%. They were almost completely protected from the neurodegeneration and motor problems seen in normal mice. The code had been cracked. The doorway had been found. And with that discovery came a clear target for a new kind of therapy.

A Cancer Weapon for a Brain Disease

Discovering the molecular doorway was a massive step. But what makes this story so powerful is the immediate, almost unbelievable connection to a treatment that already exists. This is thanks to a clever and increasingly common strategy in medicine called “drug repurposing.” Instead of spending 10 to 15 years and billions of dollars creating a new drug from scratch, researchers can test existing, FDA-approved drugs for new uses. It’s a way to dramatically speed up the journey from a lab discovery to a potential therapy for patients.

As the Johns Hopkins team zeroed in on the Lag3 protein, they were aware of a remarkable coincidence: Lag3 was already a well-known target in cancer treatment. This led them directly to a specific drug called Opdualag, an immunotherapy approved for treating advanced melanoma. In cancer, Lag3 acts as a “brake” on the immune system’s T-cells, stopping them from attacking tumors. The drug contains an antibody, relatlimab, that works by blocking this brake, essentially unleashing the T-cells to do their job.

This is where the researchers made an inspired conceptual leap. They knew the antibody physically obstructs the Lag3 protein on immune cells to promote an attack. They wondered: could this same antibody also be used to physically obstruct the Lag3 “door handle” on neurons to prevent an invasion? Could a drug designed to act as an accelerator in one context be repurposed to act as a shield in another?

They tested the idea in their mouse model of Parkinson’s, and the results were a resounding success. The antibody effectively jammed the molecular doorway, preventing the toxic alpha-synuclein clumps from getting into healthy brain cells. In fact, it worked even better than simply deleting the Lag3 gene. As neuroscientist Ted Dawson explains, “The anti-Lag3 antibody was successful in preventing further spread of alpha-synuclein seeds in the mouse models and exhibited better efficacy than Lag3-depletion because of Aplp1’s close association with Lag3.” In other words, the antibody didn’t just block one of the handles; it disrupted the entire lock mechanism, offering a precise and potent way to intervene.

The Realistic Path Forward

The success in mouse models is thrilling, but it’s important to hold this excitement with a dose of realism. The journey from a laboratory discovery to an approved therapy for people is a long and careful one. The next crucial phase involves moving toward clinical trials in humans, which comes with its own set of challenges. First, researchers need to be sure the antibody can cross the brain’s formidable protective shield, the blood-brain barrier, in large enough amounts to be effective. They also have to thoroughly evaluate the long-term safety of using a potent immune-modifying drug like this, especially for older adults who might take it for many years.

What’s particularly exciting is that the potential impact of this discovery may reach even beyond Parkinson’s. Researchers have noted that this same Lag3 receptor also binds to tau, the toxic protein responsible for Alzheimer’s disease. This opens up the possibility that the very same strategy—blocking the Aplp1-Lag3 doorway—could one day be used to fight two of the most feared diseases of aging.

It’s also important to see this breakthrough not as a single magic bullet, but as one powerful tool in a growing arsenal. The future of treating Parkinson’s likely won’t be a single cure, but a personalized “cocktail” of therapies. This might include advanced forms of Deep Brain Stimulation (DBS), gene therapies to replace lost cells, and other promising drugs repurposed from fields like diabetes research. The strategy of blocking this gateway could become a cornerstone of this new, comprehensive approach.

Ultimately, this discovery represents a profound shift in strategy. For more than 50 years, the standard treatment has been a form of damage control—replacing the dopamine that’s lost but doing nothing to stop the cells from dying in the first place. This new approach is about containment. By blocking the spread of toxic proteins from cell to cell, the goal is to build a firewall around the pathology, protecting healthy brain tissue. If started early enough, a strategy like this could preserve brain function for decades, fundamentally changing what it means to live with a Parkinson’s diagnosis.

Blocking Interference to Restore Harmony

On its surface, this is a story about proteins and antibodies. But if we look deeper, this breakthrough invites us to see the body not as a machine that breaks, but as a system of profound intelligence. The molecular doorway used by Parkinson’s isn’t a design flaw; it’s a sophisticated communication channel that gets hijacked. The disease begins when a toxic, misfolded protein sends a corrupt signal through this channel—a message of chaos instead of function. It’s a tragic miscommunication at the most fundamental level.

From this viewpoint, the therapy takes on a new meaning. The antibody isn’t a crude tool that “fixes” the cell, but an elegant shield that simply blocks the toxic message. By removing this interference, it allows the cell’s own innate intelligence—its inborn wisdom to self-regulate and heal—to reassert itself. This provides a stunning parallel to mind-body principles, where the goal is often to clear energetic or mental blockages to allow the body’s natural state of health to flourish.

Ultimately, this breakthrough is both scientific and deeply hopeful. It validates a worldview that sees the body as an active, intelligent, self-healing system that we can partner with. It’s an invitation to look beyond our symptoms to the underlying patterns of communication within us, encouraging us to consider how we can all work to remove interference—be it chronic stress, environmental toxins, or disruptive thoughts—to allow our own innate intelligence to flow, restoring harmony from the cell to the soul.

Source:

1. Mao, X., Gu, H., Kim, D., Kimura, Y., Wang, N., Xu, E., Kumbhar, R., Ming, X., Wang, H., Chen, C., Zhang, S., Jia, C., Liu, Y., Bian, H., Karuppagounder, S. S., Akkentli, F., Chen, Q., Jia, L., Hwang, H., . . . Dawson, T. M. (2024). Aplp1 interacts with Lag3 to facilitate transmission of pathologic α-synuclein. Nature Communications, 15(1). https://doi.org/10.1038/s41467-024-49016-3

Loading...